Oramed Pharmaceuticals Inc.

ORMP

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001176309

SEC filings (opens in a new tab)

No open-market purchases or sales by Oramed Pharmaceuticals Inc. insiders were filed in the last 90 days; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Oramed Pharmaceuticals Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025 All holders in Q3 2025

13F holders of ORMP: Q3 2025 compared with Q4 2025
Measure	Q3 2025	Q4 2025	Change
Holders	47	57	+10
Shares	9.21M	13.1M	+3.85M (+41.8%)
Value	$24.3M	$37.2M	+$12.9M (+53.1%)

New holders (15)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to ORMP in Q4 2025
Institution	Shares	Value	% of portfolio
Gem Investment Advisors, LLC	1,998,802	$5.70M	5.40%
SB Capital Management Inc	1,900,000	$5.42M	1.98%
Marshall Wace, LLP	259,055	$738.3K	0.00%
HRT Financial LP	46,091	$131.0K	0.00%
Quadrature Capital Ltd	41,734	$118.9K	0.00%
Point72 Asset Management, L.P.	25,442	$72.5K	0.00%
Two Sigma Securities, LLC	23,143	$66.0K	0.01%
Redwood Family Wealth LLC	23,000	$65.5K	0.06%
Prelude Capital Management, LLC	21,613	$61.6K	0.00%
Algert Global LLC	12,068	$34.4K	0.00%
N.E.W. Advisory Services LLC	3,200	$9.12K	0.00%
Pioneer Family Office, LLC	3,000	$8.55K	0.01%
Simplex Trading, LLC	1,145	$3.26K	0.00%
Caitlin John, LLC	1,000	$2.85K	0.00%
Tower Research Capital LLC (TRC)	693	$1.98K	0.00%

Sold out (5)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of ORMP in Q4 2025
Institution	Shares, Q3 2025	Value, Q3 2025
Royal Bank of Canada	3,483	$9.00K
Newbridge Financial Services Group, Inc.	1,000	$2.64K
Allworth Financial LP	300	$792
Hopwood Financial Services, Inc.	200	$528
Citigroup Inc	4	$11